Corporation
Bayer Inc.
- Meetings this Parliament
- 17
- With MPs
- 4
- Since Nov 2021
- 27
- Active registrations
- 1
Most recent reported meeting: Sep 29, 2026.
Lobbying by Bayer Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Oct 1, 2026
Filed by Viktoria Friedrich, Country President and General Manager - Pharmaceutical Division
Lobbyists
- Adrian Kupesic · Director, Public and Government Affairs
- Brandon Levac · Head, Market Access and Government Affairs
- Shurjeel Choudhri · Head, Medical & Scientific Affairs
- Viktoria Friedrich · Country President and General Manager - Pharmaceutical Division
Institutions they may lobby: Canada Revenue Agency (CRA), Canadian Food Inspection Agency (CFIA), Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Invest in Canada Hub, National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (5)Hide details
- Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
- Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.
- Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
- Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada
- Communicating with government officials on Bill S-243, An Act to establish a national framework for women’s health in Canada. Providing guidance, subject matter expertise and relevant information to help inform future policy development.
Registration 955828-4969-34. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Viktoria Friedrich (21), Alok Kanti (6).
-
Reported by Viktoria Friedrich · In-house (corporation)
- Julie Harb · Senior Policy Advisor, Prime Minister's Office (PMO)
Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada Read more
Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.
-
Reported by Viktoria Friedrich · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines. Read more
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
-
Reported by Viktoria Friedrich · In-house (corporation)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy. Read more
Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada
Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
-
Reported by Viktoria Friedrich · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians. Read more
Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
-
Reported by Viktoria Friedrich · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians. Read more
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada
-
Reported by Viktoria Friedrich · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy. Read more
Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.
-
Reported by Viktoria Friedrich · In-house (corporation)
- Simone Racanelli · Senior Advisor, Stakeholder Relations, Innovation, Science and Economic Development Canada (ISED)
Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians. Read more
Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
-
Reported by Viktoria Friedrich · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- David McFarlane · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
Advocacy as it relates to the US Administration’s Most Favored Nation drug pricing policy and its potential impact for Canada Read more
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy.
Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.
-
Reported by Viktoria Friedrich · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Communicating with government officials on policies and/or programs that support life science research and development conducted in Canada, including manufacturing and workforce development, including measures pertaining to Canada’s Biomanufacturing and Life Sciences Strategy. Read more
Domestic and international trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
Communicating, in general, with officials about research, development and innovation in Canada's life sciences and biopharmaceutical sectors, including the impact these sectors have on the Canadian economy and health of Canadians.
-
Reported by Viktoria Friedrich · In-house (corporation)
- Danièle Henkel · Senator, Senate of Canada
Communicating with government officials on Bill S-243, An Act to establish a national framework for women’s health in Canada. Providing guidance, subject matter expertise and relevant information to help inform future policy development. Read more
-
Reported by Viktoria Friedrich · In-house (corporation)
- Manuela Tomic · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Viktoria Friedrich · In-house (corporation)
- Miro Froehlich · Director of Policy, Privy Council Office (PCO)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Viktoria Friedrich · In-house (corporation)
- Tom Kmiec · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Viktoria Friedrich · In-house (corporation)
- Anna Roberts · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Viktoria Friedrich · In-house (corporation)
- Parm Bains · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Viktoria Friedrich · In-house (corporation)
- Chris Bittle · Member of Parliament
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Viktoria Friedrich · In-house (corporation)
- Noemie Fiset-Tremblay · Chief of Staff to the Minister, Employment and Social Development Canada (ESDC)
Canadian Labour Code: Occupational Health and Safety. Elevating awareness of treatment and therapeutic availability.
-
Reported by Viktoria Friedrich · In-house (corporation)
- François-Philippe Champagne · Minister of Finance, Finance Canada (FIN)
International trade policy and free trade agreements with respect to the biopharmaceutical industry
-
Reported by Viktoria Friedrich · In-house (corporation)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
International trade policy and free trade agreements with respect to the biopharmaceutical industry
-
Reported by Viktoria Friedrich · In-house (corporation)
- Tom Kmiec · Member of Parliament
- Blaine Calkins · Member of Parliament
- Stephen Ellis · Member of Parliament, House of Commons
- Earl Dreeshan · Member of Parliament, House of Commons
HealthIntellectual PropertyScience and Technology
-
Reported by Viktoria Friedrich · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
HealthScience and Technology
-
Reported by Alok Kanti · In-house (corporation)
- Iqwinder Gaheer · Member of Parliament
HealthIndustryIntellectual PropertyScience and Technology
-
Reported by Alok Kanti · In-house (corporation)
- Judy A. Sgro · Member of Parliament
Consumer IssuesHealthIndustryScience and Technology
-
Reported by Alok Kanti · In-house (corporation)
- Judy A. Sgro · Member of Parliament
HealthIndustryScience and Technology
-
Reported by Alok Kanti · In-house (corporation)
- Iqwinder Gaheer · Member of Parliament
AgricultureConsumer IssuesHealthIndustryIntellectual PropertyResearch and DevelopmentScience and Technology
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.